115 related articles for article (PubMed ID: 37736329)
1. Erratum: Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum].
Diabetes Metab Syndr Obes; 2023; 16():2833-2834. PubMed ID: 37736329
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice.
Niu S; Ren Q; Chen S; Pan X; Yue L; Chen X; Li Z; Zhen R
Diabetes Metab Syndr Obes; 2023; 16():2549-2560. PubMed ID: 37645238
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum: The Microbiota and It's Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease.
Gu C; Zhou Z; Yu Z; He M; He L; Luo Z; Xiao W; Yang Q; Zhao F; Li W; Shen L; Han J; Cao S; Zuo Z; Deng J; Yan Q; Ren Z; Zhao M; Yu S
Front Cell Infect Microbiol; 2022; 12():972118. PubMed ID: 35865827
[TBL] [Abstract][Full Text] [Related]
4. Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models.
Kim DY; Chung KS; Park JY; Gee HY
Biomed Pharmacother; 2023 May; 161():114445. PubMed ID: 36842353
[TBL] [Abstract][Full Text] [Related]
5. MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH.
Wang Y; Shen QL; Xin Q; Sun B; Zhang S; Fang QH; Shi YX; Niu WY; Lin JN; Li CJ
J Mol Endocrinol; 2022 Oct; 69(3):415-430. PubMed ID: 35900373
[TBL] [Abstract][Full Text] [Related]
6. Erratum: Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia: Erratum.
Medicine (Baltimore); 2017 Jun; 96(23):e7231. PubMed ID: 31305674
[TBL] [Abstract][Full Text] [Related]
7. Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6
Li T; Lin X; Shen B; Zhang W; Liu Y; Liu H; Wang Y; Zheng L; Zhi F
Front Immunol; 2023; 14():1139000. PubMed ID: 36911688
[TBL] [Abstract][Full Text] [Related]
8. Erratum: Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy [Corrigendum].
Drug Des Devel Ther; 2021; 15():231. PubMed ID: 33505157
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling.
Giles DA; Moreno-Fernandez ME; Stankiewicz TE; Graspeuntner S; Cappelletti M; Wu D; Mukherjee R; Chan CC; Lawson MJ; Klarquist J; Sünderhauf A; Softic S; Kahn CR; Stemmer K; Iwakura Y; Aronow BJ; Karns R; Steinbrecher KA; Karp CL; Sheridan R; Shanmukhappa SK; Reynaud D; Haslam DB; Sina C; Rupp J; Hogan SP; Divanovic S
Nat Med; 2017 Oct; 23(10):1241. PubMed ID: 28985207
[TBL] [Abstract][Full Text] [Related]
10. Erratum: Association of
Diabetes Metab Syndr Obes; 2022; 15():885-886. PubMed ID: 35340988
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum to "Caffeoylquinic Acid-Rich Extract of
Lee YJ; Jang YN; Han YM; Kim HM; Jeong JM; Son MJ; Jin CB; Kim HJ; Seo HS
PPAR Res; 2019; 2019():5317126. PubMed ID: 31781179
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to "Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease".
Masarone M; Rosato V; Dallio M; Gravina AG; Aglitti A; Loguercio C; Federico A; Persico M
Oxid Med Cell Longev; 2021; 2021():9757921. PubMed ID: 34373772
[TBL] [Abstract][Full Text] [Related]
13. Erratum: Differences in the Association Among the Vitamin D Concentration, Dietary Macronutrient Consumption, and Metabolic Syndrome Depending on Pre- and Postmenopausal Status in Korean Women: A Cross-Sectional Study [Corrigendum].
Diabetes Metab Syndr Obes; 2020; 13():4005. PubMed ID: 33149639
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhang Y; Liu X; Zhang H; Wang X
Front Endocrinol (Lausanne); 2022; 13():836455. PubMed ID: 35282455
[TBL] [Abstract][Full Text] [Related]
15. Corrigendum: Revealing the mechanism of Huazhi Rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16S rRNA, metagenomic sequencing and network pharmacology.
Liu Y; Tan Y; Huang J; Wu C; Fan X; Stalin A; Lu S; Wang H; Zhang J; Zhang F; Wu Z; Li B; Huang Z; Chen M; Cheng G; Mou Y; Wu J
Front Pharmacol; 2023; 14():1243304. PubMed ID: 37564177
[TBL] [Abstract][Full Text] [Related]
16. Erratum: Resveratrol Prevents Cognitive Impairment in Type 2 Diabetic Mice by Upregulating Nrf2 Expression and Transcriptional Level [Corrigendum].
Diabetes Metab Syndr Obes; 2020; 13():2057. PubMed ID: 32606864
[TBL] [Abstract][Full Text] [Related]
17. Corrigendum to "The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease".
Lewis JE; Atlas SE; Higuera OL; Fiallo A; Rasul A; Farooqi A; Kromo O; Lantigua LA; Tiozzo E; Woolger JM; Goldberg S; Mendez A; Rodriguez AE; Konefal J
Evid Based Complement Alternat Med; 2020; 2020():9575878. PubMed ID: 32328144
[TBL] [Abstract][Full Text] [Related]
18. Erratum to "Evaluation of the Mechanism of Modified Lingguizhugan Decoction in the Treatment of Nonalcoholic Fatty Liver Disease".
Yang F; Zhou J; Su B; Zhang Q; Luo X; Wang F; Huang J; Huang W
Evid Based Complement Alternat Med; 2022; 2022():9782896. PubMed ID: 35996404
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.
Saudi J Gastroenterol; 2018; 24(4):255. PubMed ID: 30052239
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis.
Radlinger B; Ress C; Folie S; Salzmann K; Lechuga A; Weiss B; Salvenmoser W; Graber M; Hirsch J; Holfeld J; Kremser C; Moser P; Staudacher G; Jelenik T; Roden M; Tilg H; Kaser S
Diabetologia; 2023 Apr; 66(4):754-767. PubMed ID: 36525084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
